Dermatology

Original Paper

Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011

Armstrong A.W.a · Schupp C.a · Bebo B.b

Author affiliations

aDepartment of Dermatology, University of California Davis, Sacramento, Calif., and bNational Psoriasis Foundation, Portland, Oreg., USA

Keywords: ComorbiditiesCardiovascular diseaseImmune-mediated comorbiditiesPsoriasisPsoriatic arthritis

Related Articles for ""
Dermatology 2012;225:121–126
https://doi.org/10.1159/000342180

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 30, 2012
Accepted: July 23, 2012
Published online: October 26, 2012
Issue release date: November 2012

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 3

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Abstract

Background: Studies examining comorbidities among psoriasis patients with varying disease severities measured by body surface area (BSA) are lacking. Objective: To examine the association between psoriasis severity and comorbid conditions, including rheumatologic, cardiovascular and other immune-mediated diseases. Methods: From 2003 to 2011, the National Psoriasis Foundation conducted surveys among 5,604 psoriasis patients. The combined surveys represented the largest study to date that used BSA as a direct measure of psoriasis severity for comorbidity assessment. Results: Over 86% of psoriatic arthritis (PsA) patients reported presenting with psoriasis prior to PsA; the diagnosis of psoriasis preceded that of PsA by a mean period of 14.6 years. Compared to those with mild psoriasis, patients with moderate-to-severe psoriasis had significantly increased adjusted odds of PsA (moderate: odds ratio, OR: 1.21, 95% confidence interval, CI: 1.04–1.41; severe: OR: 2.32, 95% CI: 1.98–2.70). Patients with severe psoriasis had increased adjusted odds of diabetes (OR: 1.5, 95% CI: 1.08–2.08) and cardiovascular disease (OR: 1.5, 95% CI: 1.01–2.24) compared to those with mild-to-moderate psoriasis. Odds of rheumatoid arthritis, ankylosing spondylitis, lupus, Crohn’s disease and multiple sclerosis were not significantly increased in patients with severe psoriasis. Conclusion: Compared to those with mild-to-moderate psoriasis, patients with severe psoriasis are at increased odds of PsA, diabetes and cardiovascular diseases.

© 2012 S. Karger AG, Basel

References

  1. Raychaudhuri SP, Farber EM: The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16–17.
    External Resources
  2. Naldi L, Mercuri SR: Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010;23:114–118.
    External Resources
  3. Gottlieb AB, Dann F: Comorbidities in patients with psoriasis. Am J Med 2009;122:1150.e1–1150.e9.
    External Resources
  4. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735–1741.
    External Resources
  5. Ahlehoff O, Gislason GH, Charlot M, Jorgensen CH, Lindhardsen J, Olesen JB, Abildstrom SZ, Skov L, Torp-Pedersen C, Hansen PR: Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011;270:147–157.
    External Resources
  6. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM: Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 2010;31:1000–1006.
    External Resources
  7. Krenzer S, Radtke M, Schmitt-Rau K, Augustin M: Characterization of patient-reported outcomes in moderate to severe psoriasis. Dermatology 2011;223:80–86.
    External Resources
  8. Finlay AY, Khan GK: Dermatology life quality index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–216.
    External Resources
  9. Chandran V, Gladman DD: Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire: a report from the GRAPPA 2009 annual meeting. J Rheumatol 2011;38:546–547.
    External Resources
  10. Dominguez P, Husni ME, Garg A, Qureshi AA: Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire and the role of dermatologists: a report from the GRAPPA 2009 annual meeting. J Rheumatol 2011;38:548–550.
    External Resources
  11. Helliwell PS: Psoriasis Epidemiology Screening Tool (PEST): a report from the GRAPPA 2009 annual meeting. J Rheumatol 2011;38:551–552.
    External Resources
  12. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T: Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53:573.
    External Resources
  13. Solomon DH, Love TJ, Canning C, Schneeweiss S: Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010;69:2114–2117.
    External Resources
  14. Qureshi AA, Choi HK, Setty AR, Curhan GC: Psoriasis and the risk of diabetes and hypertension: a prospective study of us female nurses. Arch Dermatol 2009;145:379–382.
    External Resources
  15. Altobelli E, Petrocelli R, Maccarone M, Altomare G, Argenziano G, Giannetti A, Peserico A, Vena GA, Tiberti S, Chimenti S, Peris K: Risk factors of hypertension, diabetes and obesity in Italian psoriasis patients: a survey on socio-demographic characteristics, smoking habits and alcohol consumption. Eur J Dermatol 2009;19:252–256.
    External Resources
  16. Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, Meyerovitch J: Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008;22:585–589.
    External Resources
  17. Brauchli YB, Jick SS, Meier CR: Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008;159:1331–1337.
    External Resources
  18. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, Kremer E, Heymann A: The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007;56:629–634.
    External Resources
  19. Hajer GR, van Haeften TW, Visseren FL: Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008;29:2959–2971.
    External Resources
  20. Zhao YF, Feng DD, Chen C: Contribution of adipocyte-derived factors to beta-cell dysfunction in diabetes. Int J Biochem Cell Biol 2006;38:804–819.
    External Resources
  21. Tobin AM, Veale DJ, Fitzgerald O, Rogers S, Collins P, O’Shea D, Kirby B: Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010;37:1386–1394.
    External Resources
  22. Kimball AB, Wu Y: Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. Int J Dermatol 2009; 48:1147–1156.
    External Resources
  23. Lin HW, Wang KH, Lin HC: Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. J Am Acad Dermatol 2011;64:495–501.
    External Resources
  24. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735–1741.
    External Resources
  25. Nilsson J, Hansson GK: Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med 2008;263:464–478.
    External Resources
  26. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC: A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 2011;20:544–549.
    External Resources
  27. Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009;361:496–509.
    External Resources
  28. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC: Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 2011;63:1–9.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 30, 2012
Accepted: July 23, 2012
Published online: October 26, 2012
Issue release date: November 2012

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 3

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2012, Vol.225, No. 2

November 2012

Article

TAP Icon This Article is Part of
Recommend This
TOP